Scientific Opinion on the substantiation of a health claim related to Lactobacillus casei strain Shirota and maintenance of the upper respiratory tract defence against pathogens by maintaining immune defences pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 8, Issue 10, 2010, Pages

[No Author Info available]

Author keywords

fermented milk product; health claims; Lactobacillus casei; upper respiratory tract infections

Indexed keywords

EID: 84860451368     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2010.1860     Document Type: Article

References (24)

1. Consumentenbond, 2006. Probiotische zuiveldranken.
2. Fujimoto J, Matsuki T, Sasamoto M, Tomii Y and Watanabe K, 2008. Identification and quantification of Lactobacillus casei strain Shirota in human feces with strainspecific primers derived from randomly amplified polymorphic DNA. International Journal of Food Microbiology, 126, 210–215.
3. Gleeson M, Bishop NC, Oliveira M and Tauler P, 2009. Daily probiotic (Lactobacillus casei Shirota) reduces infection incidence in athletes (unpublished).
4. Hori T, Kiyoshima J, Shida K and Yasui H, 2002. Augmentation of cellular immunity and reduction of influenza virus titer in aged mice fed Lactobacillus casei strain Shirota. Clinical and Diagnostic Laboratory Immunology, 9, 105–108.
5. Hori T, Kiyoshima J, Shida, K and Yasui H, 2001. Effect of intranasal administration of Lactobacillus casei Shirota on influenza virus infection of upper respiratory tract in mice. Clinical and Diagnostic Laboratory Immunology, 8, 593–597.
6. Ivory K, Chambers SJ, Pin C, Prieto E. Arques JL and Nicoletti C, 2008. Oral delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. Clin. Exp. Allergy, 38, 1282–1289.
7. JCICSB (Judicial Commission of the International Committee on Systematics of Bacteria), 2008. The type strain of Lactobacillus casei is ATCC 393, ATCC 334 cannot serve as the type because it represents a different taxon, the name Lactobacillus paracasei and its subspecies name are not rejected and the revival of the name ‘Lactobacillus zeae’ contravenes Rules 51b (1) and (2) of the International Code of Nomenclature of Bacteria. Opinion 82. International Journal of Systematic and Evolutionary Microbiology, 58, 1764–1765.
8. Kawami K, 1999. Part I Properties of Lactobacillus casei, Section 6 Culture and fermentation. In: Lactobacillus casei Shirota – Intestinal flora and human health. Ed Yakult Central Institute for Microbiological Research, Kyoto, 87–92.
9. Matsuzaki T, Saito M, Usuku K, Nose H, Izumo S, Arimura K and Osame M, 2005. A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. Journal of the Neurological Sciences, 237, 75–81.
10. Nagao F, Nakayama M, Muto T and Okumura K, 2000. Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the immune system in healthy human subjects. Bioscience, Biotechnology, and Biochemistry, 64, 2706–2708.
11. Reuter G, 1997. Present and future of probiotics in Germany and in Central Europe. Bioscience and Microflora, 16, 43–51.
12. Sato T, Shirasawa Y, Kiwaki M and Sato S, 2004. Genome analysis of Lactobacillus casei strain Shirota and Bifidobacterium breve strain Yakult [in Japanese]. Seibutsu-kogakukaishi, 82, 421–422.
13. Shimizu-Kadota M, Kiwaki M, Hirokawa H and Tsuchida N, 1985. ISL1: a new transposable element in Lactobacillus casei. Molecular and General Genetics, 200, 193–198.
14. Shimizu-Kadota M, Kiwaki M, Sawaki S, Shirasawa Y, Shibahara-Sone H and Sako T, 2000. Insertion of bacteriophage phiFSW into the chromosome of Lactobacillus casei strain Shirota (S-1): characterization of the attachment sites and the integrase gene. Gene, 249, 127–134.
15. Spanhaak S, Havenaar R and Schaafsma G, 1998. The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. European Journal of Clinical Nutrition, 52, 899–907.
16. Stadlbauer V, Mookerjee, RP, Hodges SJ, Wright G, Davies NA and Jalan R, 2008. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. Journal of Hepatology, 48, 945–951.
17. Takeda K, Suzuki T, Shimada SI, Shida K, Nanno M and Okumura K, 2006. Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota. Clinical and Experimental Immunology, 146, 109–115.
18. Tuohy KM, Pinart-Gilberga M, Jones M, Hoyles L, McCartney AL and Gibson GR, 2007. Survivability of a probiotic Lactobacillus casei in the gastrointestinal tract fo healthy human volunteers and its impact on the faecal microflora. Journal of Applied Microbiology, 102, 1026–1032.
19. van Gils L, Dirven K, Coenen S and van Rouen P, 2009. Pilot study to investigate the feasibility of a study protocol investigating the adjuvant effect of Lactobacillus casei Shirota on the efficacy of influenza vaccination in elderly (unpublished).
20. van Puyenbroeck K, Beunckens C, Coenen S, Michiels B, Hens N, Molenberghs G, van Royen P and Verhoeven V, 2009. Efficacy of daily intake of L.casei Shirota on respiratory symptoms and influenza vaccination immune response: a randomized double-blind placebo-controled trial in healthy elderly nursing home residents (unpublished).
21. Watanabe T and Mike A, 1999. Part I Properties of Lactobacillus casei, Section 2 Taxonomy. In: Lactobacillus casei Shirota – Intestinal flora and human health. Ed Yakult Central Institute for Microbiological Research, Kyoto, 3–23.
22. Yasuda E, Serata M and Sako T, 2008. Suppressive effect on activation of macrophages by Lactobacillus casei strain Shirota genes determining the synthesis of cell wall associated polysaccharides. Applied and Environmental Microbiology, 74, 4746–4755.
23. Yasui H, Kiyoshima J and Hori T, 2004. Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota. Clinical and Diagnostic Laboratory Immunology, 11, 675–679.
24. Yuki N, Watanabe K, Mike A, Tagami Y, Tanaka R, Ohwaki M and Morotomi M, 1999. Survival of a probiotic, Lactobacillus casei strain Shirota, in the gastrointestinal tract:selective isolation from faeces and identification using monoclonal antibodies. International Journal of Food Microbiology, 48, 51–57.